ORCID as entered in ROS

Select Publications
2025, 'Aggressive pituitary tumours and pituitary carcinomas: molecular insights guiding management and the role of precision oncology', Molecular and Cellular Endocrinology, 607, http://dx.doi.org/10.1016/j.mce.2025.112598
,2025, 'Assessing the clinical application of the PANOMEN 3 classification in a large cohort of pituitary tumors.', Eur J Endocrinol, 193, pp. 56 - 64, http://dx.doi.org/10.1093/ejendo/lvaf122
,2025, 'Pituitary incidentaloma: a Pituitary Society international consensus guideline statement.', Nat Rev Endocrinol, http://dx.doi.org/10.1038/s41574-025-01134-8
,2025, 'Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas', European Journal of Endocrinology, 192, pp. R45 - R78, http://dx.doi.org/10.1093/ejendo/lvaf100
,2025, 'FGFR1 variation in the divergent settings of congenital hypopituitarism and pituitary tumours', Pituitary, 28, http://dx.doi.org/10.1007/s11102-025-01498-0
,2025, 'Frailty and pituitary surgery: a systematic review', Pituitary, 28, http://dx.doi.org/10.1007/s11102-025-01507-2
,2025, 'Delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endogenous Cushing's syndrome: a position statement', European Journal of Endocrinology, 192, pp. R17 - R27, http://dx.doi.org/10.1093/ejendo/lvaf017
,2025, 'Approach to the Patient With Suspected Hypotonic Polyuria', Journal of Clinical Endocrinology and Metabolism, 110, pp. e506 - e514, http://dx.doi.org/10.1210/clinem/dgae565
,2025, 'Inflammation of adenohypophysis is commonly associated with headache in surgically managed Rathke’s cleft cysts', Pituitary, 28, http://dx.doi.org/10.1007/s11102-024-01486-w
,2024, 'Quality of life in non-functioning pituitary adenoma: A systematic review', Neurosurgical Review, 47, http://dx.doi.org/10.1007/s10143-024-03126-0
,2024, 'Approach to the Patient: New Era Emerges for Craniopharyngioma Management', Journal of Clinical Endocrinology and Metabolism, 109, pp. 2986 - 2996, http://dx.doi.org/10.1210/clinem/dgae503
,2024, 'Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus', Clinical Endocrinology, 101, pp. 443 - 445, http://dx.doi.org/10.1111/cen.14819
,2024, 'Increased Prevalence of Germline Pathogenic CHEK2 Variants in Individuals With Pituitary Adenomas', Journal of Clinical Endocrinology and Metabolism, 109, pp. 2720 - 2728, http://dx.doi.org/10.1210/clinem/dgae268
,2024, 'Pituitary tumours without distinct lineage differentiation express stem cell marker SOX2', Pituitary, 27, pp. 248 - 258, http://dx.doi.org/10.1007/s11102-024-01385-0
,2024, 'Headache in Patients with Sellar Disease: Clinicomorphological Predictors of Headache and the Outcome of Endoscopic Transsphenoidal Surgery', Journal of Neurological Surgery Part B Skull Base, 85, pp. 247 - 254, http://dx.doi.org/10.1055/a-2036-0652
,2024, 'Author Correction: Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement (Nature Reviews Endocrinology, (2023), 19, 12, (722-740), 10.1038/s41574-023-00886-5)', Nature Reviews Endocrinology, 20, pp. 62, http://dx.doi.org/10.1038/s41574-023-00916-2
,2023, 'Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement', Nature Reviews Endocrinology, 19, pp. 722 - 740, http://dx.doi.org/10.1038/s41574-023-00886-5
,2023, 'Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group to Consider Renaming Diabetes Insipidus', Hormone Research in Paediatrics, 96, pp. 423 - 425, http://dx.doi.org/10.1159/000527139
,2023, 'Predictors of pituitary tumour behaviour: An analysis from long-Term follow-up in 2 tertiary centres', European Journal of Endocrinology, 189, pp. 106 - 114, http://dx.doi.org/10.1093/ejendo/lvad079
,2023, 'Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?-that is the question', European Journal of Endocrinology, 188, pp. C5 - C8, http://dx.doi.org/10.1093/ejendo/lvad042
,2023, 'Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group for Renaming Diabetes Insipidus', Journal of Clinical Endocrinology and Metabolism, 108, pp. 1 - 3, http://dx.doi.org/10.1210/clinem/dgac547
,2023, 'Pituitary tumours: molecular and genetic aspects', Journal of Endocrinology, 257, http://dx.doi.org/10.1530/JOE-22-0291
,2023, 'The evolution in pituitary tumour classification: a clinical perspective.', Endocr Oncol, 3, pp. e220079, http://dx.doi.org/10.1530/EO-22-0079
,2022, 'Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group for Renaming Diabetes Insipidus.', J Clin Endocrinol Metab, 108, pp. 1 - 3, http://dx.doi.org/10.1210/clinem/dgac547
,2022, 'Changing the name of diabetes insipidus', Pituitary, 25, pp. 777 - 779, http://dx.doi.org/10.1007/s11102-022-01276-2
,2022, 'Development of a cost-effective diagnostic algorithm incorporating transcription factor immunohistochemistry in the evaluation of pituitary tumours', Pituitary, 25, pp. 997 - 1003, http://dx.doi.org/10.1007/s11102-022-01284-2
,2022, 'Temozolomide in aggressive pituitary tumours and pituitary carcinomas', Best Practice and Research Clinical Endocrinology and Metabolism, 36, http://dx.doi.org/10.1016/j.beem.2022.101713
,2022, 'Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus', Endocrine Connections, 11, http://dx.doi.org/10.1530/EC-22-0378
,2022, 'Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus.', Eur J Endocrinol, 187, pp. P1 - P3, http://dx.doi.org/10.1530/EJE-22-0751
,2022, 'Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients', European Journal of Endocrinology, 187, pp. 593 - 605, http://dx.doi.org/10.1530/EJE-22-0440
,2022, 'MEN4, the MEN1 Mimicker: A Case Series of Three Phenotypically Heterogenous Patients With Unique CDKN1B Mutations', Journal of Clinical Endocrinology and Metabolism, 107, pp. 2339 - 2349, http://dx.doi.org/10.1210/clinem/dgac162
,2022, 'Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement', European Journal of Endocrinology, 186, pp. 35 - 52, http://dx.doi.org/10.1530/EJE-21-1186
,2022, 'Letter to the Editor From Raven et al: "Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine"', Journal of Clinical Endocrinology and Metabolism, 107, pp. E1767 - E1768, http://dx.doi.org/10.1210/clinem/dgab822
,2022, 'Female Representation: Australian Diabetes and Endocrinology Societies', Frontiers in Endocrinology, 13, http://dx.doi.org/10.3389/fendo.2022.842909
,2022, 'Editorial: Refractory Pituitary Adenoma—Current Challenges and Emerging Treatments', Frontiers in Endocrinology, 13, http://dx.doi.org/10.3389/fendo.2022.868174
,2022, 'Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas', Pituitary, 25, pp. 64 - 73, http://dx.doi.org/10.1007/s11102-021-01170-3
,2022, 'Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus', Archives of Endocrinology and Metabolism, 66, pp. 868 - 870, http://dx.doi.org/10.20945/2359-3997000000528
,2022, 'Low but not undetectable early postoperative nadir serum cortisol predicts sustained remission in Cushing's disease.', Endocr Oncol, 2, pp. 19 - 31, http://dx.doi.org/10.1530/EO-21-0026
,2021, 'Consensus on diagnosis and management of Cushing's disease: a guideline update', Lancet Diabetes and Endocrinology, 9, pp. 847 - 875, http://dx.doi.org/10.1016/S2213-8587(21)00235-7
,2021, 'Childhood-onset prolactinomas—Should earlier surgery be considered?', Clinical Endocrinology, 95, pp. 571 - 573, http://dx.doi.org/10.1111/cen.14477
,2021, 'Towards precision medicine for clinically non-functioning pituitary tumours', Clinical Endocrinology, 95, pp. 398 - 409, http://dx.doi.org/10.1111/cen.14472
,2021, 'Assessment of magnetic resonance imaging criteria for the diagnosis of cavernous sinus invasion by pituitary tumors', Journal of Clinical Neuroscience, 90, pp. 262 - 267, http://dx.doi.org/10.1016/j.jocn.2021.06.010
,2021, 'Multidisciplinary Team Care in the Surgical Management of Pituitary Adenoma', Journal of Neurological Surgery Part B Skull Base, 82, pp. 295 - 302, http://dx.doi.org/10.1055/s-0039-1700498
,2021, 'Transcription Factor Immunohistochemistry in the Diagnosis of Pituitary Tumors', Journal of the Endocrine Society, 5, pp. A651 - A651, http://dx.doi.org/10.1210/jendso/bvab048.1327
,2021, 'Transcription factor immunohistochemistry in the diagnosis of pituitary tumours', European Journal of Endocrinology, 184, pp. 891 - 901, http://dx.doi.org/10.1530/EJE-20-1273
,2020, 'Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy', Frontiers in Endocrinology, 11, pp. 576027, http://dx.doi.org/10.3389/fendo.2020.576027
,2020, 'Outcomes of pituitary surgery for Cushing’s disease: a systematic review and meta-analysis', Pituitary, 23, pp. 595 - 609, http://dx.doi.org/10.1007/s11102-020-01066-8
,2020, 'Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic—an international perspective', Pituitary, 23, pp. 327 - 337, http://dx.doi.org/10.1007/s11102-020-01059-7
,2020, 'Fatal high-grade skull osteosarcoma 30 years following radiotherapy for Cushing’s disease', Endocrinology Diabetes and Metabolism Case Reports, 2020, pp. 1 - 7, http://dx.doi.org/10.1530/EDM-20-0062
,2020, 'Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician’s questions', Reviews in Endocrine and Metabolic Disorders, 21, pp. 243 - 251, http://dx.doi.org/10.1007/s11154-020-09562-9
,